title: Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
abstract: Among the most serious problems in patients with chronic kidney disease (CKD) is fragility of cortical bone caused by cortical thinning and increased cortical porosity; the cortical fragility is sometimes irreversible, with fractures generally initiating from cortical bone. Therefore, development of treatments for problems of cortical bone is urgently desired. Cortical bone has the three surfaces, including the periosteal surface, intracortical spaces and endocortical surface. Bone turnover at the endocortical surface and intracortical resorption spaces are increased as compared with that at cancellous surface. Bone growth sometimes depends on apposition at the periosteal surface. We treated hyperphosphatemia in two hemodialysis patients with adynamic bone disease with 750-1500 mg/day of lanthanum carbonate, which is a non-calcium containing phosphate binder; the treatment resulted in a decrease of the serum phosphorus levels (P levels), without significant change of the serum intact parathyroid hormone levels. We now report that treatment of these patients with lanthanum carbonate increased mineralization of the periosteal surface, increased bone mass within the intracortical resorption spaces and increased mineralization of the minimodeling surface at the endocortical surface. In addition, woven bone volume in cortical bone was decreased and mineralization of bone units, namely, osteons, was increased. Although these findings were not observed across all surfaces of the cortical bone in the patients, it is expected that lanthanum carbonate would increase the cortical stability in CKD patients, with consequent reduction in the fracture rate in these patients.
authors.affiliation: Department of Pathology, The University of Texas, Southwestern Medical Center, Dallas, TX, USA,
authors.forename: Aiji
authors.initials: A
authors.lastname: Yajima
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inaba
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tominaga
authors.forename: Motoko
authors.initials: M
authors.lastname: Tanaka
authors.forename: Shigeru
authors.initials: S
authors.lastname: Otsubo
authors.forename: Kosaku
authors.initials: K
authors.lastname: Nitta
authors.forename: Akemi
authors.initials: A
authors.lastname: Ito
authors.forename: Shigeru
authors.initials: S
authors.lastname: Satoh
mesh_terms: D000368:Aged; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy; D007811:Lanthanum / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis / Q000379:methods*; D051436:Renal Insufficiency, Chronic / Q000628:therapy
chemical_list: D010281:Parathyroid Hormone; D010758:Phosphorus; C119467:lanthanum carbonate; D007811:Lanthanum